- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Transthyretin cardiac amyloidosis
- Meeting Date: March 2021
- Public Summary Document (PSD) March 2021 PBAC Meeting - (PDF 1737KB)
- Public Summary Document (PSD) March 2021 PBAC Meeting - (Word 930KB)
Tafamidis – March 2021
Tafamidis: Capsule 61 mg; Vyndamax®
Last updated
2 July 2021